NUVL: SEC Form S-8 POS filed by Nuvalent Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for NUVL
Across the 24 sessions after earlier NUVL headlines, the stock closed higher 14 times and lower 10 times, with a median move of 1.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NUVL | SPY |
|---|---|---|---|
| Jun 24, 2026 | Nuvalent downgraded by Bernstein with a new price target | +0.1% | -0.0% |
| May 27, 2026 | Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC | +2.3% | -0.0% |
| May 22, 2026 | Bernstein initiated coverage on Nuvalent with a new price targetand 1 other headline that session | +0.9% | +0.4% |
| May 7, 2026 | Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | -1.8% | -0.3% |
| Apr 21, 2026 | Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting | -1.0% | -0.7% |
| Apr 20, 2026 | New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 | +0.6% | -0.2% |
Quantisnow market dataNASDAQ
NUVL
Nuvalent Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for NUVL
Full NUVL profile on Quantisnow Follow NUVL and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time